Let Me See: Correlation between 5-ALA Fluorescence and Molecular Pathways in Glioblastoma: A Single Center Experience.
5-ALA
IDH1
MGMT
extent of resection
fluorescence
glioblastoma
molecular pathways
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
16 Jun 2021
16 Jun 2021
Historique:
received:
15
05
2021
revised:
04
06
2021
accepted:
10
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Despite the aggressiveness of multimodal treatment, glioblastoma (GBM) is still a challenge for neurosurgeons, neurooncologists, and radiotherapists. A surgical approach is still a cornerstone in GBM therapeutic management, as the extent of resection is strongly related both to overall survival and progression-free survival. From this perspective, the use of photodynamic molecules could represent an interesting tool to achieve maximal and safe resection. Being able to trace the lesion's edges, indeed, could allow to improve the extent of resection and to minimize residual tumor while sparing normal tissue. The use of 5-aminolevulinic acid (5-ALA) as a photodynamic tracer is well established due to its strict correlation both with cellularity and metabolic activity of the GBM cell clones. Our study aims to define whether a different molecular asset of GBM (especially investigating Patients undergoing surgery for GBM removal at our Institute (Dep. Of Neurosurgery, Ospedale Città della Salute e della Scienza, University of Turin, Italy) were retrospectively reviewed. Patients with histological diagnosis confirmation and to whom 5-ALA was given before surgery were included. The whole surgical procedure was recorded and then analyzed by three different people (a medical student, a resident, and a senior surgeon with an interest in neurooncology and experience in using 5-ALA) and a score was assigned to the different degrees of intraoperative fluorescence. The degree of fluorescence was then matched with the genotype. A trend of grade 2 fluorescence (i.e., "strong") was observed in the Our results do not support the use of 5-ALA as a diagnostic tool, or a way to substitute the molecular profiling, but confirm 5-ALA as a powerful metabolic tracer, able to easily detect the pathological cells, especially in the IDH WT genotype, and in this perspective, further studies will be necessary to better describe the metabolic activity of GBM cells.
Sections du résumé
BACKGROUND
BACKGROUND
Despite the aggressiveness of multimodal treatment, glioblastoma (GBM) is still a challenge for neurosurgeons, neurooncologists, and radiotherapists. A surgical approach is still a cornerstone in GBM therapeutic management, as the extent of resection is strongly related both to overall survival and progression-free survival. From this perspective, the use of photodynamic molecules could represent an interesting tool to achieve maximal and safe resection. Being able to trace the lesion's edges, indeed, could allow to improve the extent of resection and to minimize residual tumor while sparing normal tissue. The use of 5-aminolevulinic acid (5-ALA) as a photodynamic tracer is well established due to its strict correlation both with cellularity and metabolic activity of the GBM cell clones.
OBJECTIVE
OBJECTIVE
Our study aims to define whether a different molecular asset of GBM (especially investigating
METHODS
METHODS
Patients undergoing surgery for GBM removal at our Institute (Dep. Of Neurosurgery, Ospedale Città della Salute e della Scienza, University of Turin, Italy) were retrospectively reviewed. Patients with histological diagnosis confirmation and to whom 5-ALA was given before surgery were included. The whole surgical procedure was recorded and then analyzed by three different people (a medical student, a resident, and a senior surgeon with an interest in neurooncology and experience in using 5-ALA) and a score was assigned to the different degrees of intraoperative fluorescence. The degree of fluorescence was then matched with the genotype.
RESULTS
RESULTS
A trend of grade 2 fluorescence (i.e., "strong") was observed in the
CONCLUSION
CONCLUSIONS
Our results do not support the use of 5-ALA as a diagnostic tool, or a way to substitute the molecular profiling, but confirm 5-ALA as a powerful metabolic tracer, able to easily detect the pathological cells, especially in the IDH WT genotype, and in this perspective, further studies will be necessary to better describe the metabolic activity of GBM cells.
Identifiants
pubmed: 34208653
pii: brainsci11060795
doi: 10.3390/brainsci11060795
pmc: PMC8235669
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Radiol Oncol. 2014 Jan 22;48(1):72-9
pubmed: 24587783
Photochem Photobiol. 2015 Nov;91(6):1452-7
pubmed: 26277101
Neurosurg Rev. 2018 Apr;41(2):599-604
pubmed: 28856492
Int J Cancer. 2011 Mar 1;128(5):1095-103
pubmed: 20473936
Clin Neurol Neurosurg. 2015 Dec;139:166-71
pubmed: 26489387
J Neurooncol. 2014 Feb;116(3):505-13
pubmed: 24401960
Photodiagnosis Photodyn Ther. 2016 Sep;15:73-8
pubmed: 27235278
J Neurosurg. 2011 Jul;115(1):11-7
pubmed: 21438658
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neurol Sci. 2005 May;26 Suppl 1:S40-2
pubmed: 15883692
Epilepsy Res. 2017 Feb;130:1-6
pubmed: 28073027
Lancet Oncol. 2006 May;7(5):392-401
pubmed: 16648043
Curr Opin Oncol. 2010 Nov;22(6):611-20
pubmed: 20706121
J Clin Neurosci. 2019 Dec;70:55-60
pubmed: 31537460
Brain Sci. 2021 Apr 28;11(5):
pubmed: 33925235
Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4
pubmed: 14765378
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211021605
pubmed: 34212784
J Natl Cancer Inst. 2010 Jul 7;102(13):932-41
pubmed: 20513808
Neurosurgery. 2016 Mar;78(3):401-11; discussion 411
pubmed: 26366972
Surg Technol Int. 2019 Aug 1;35:432-440
pubmed: 31373379
Surg Technol Int. 2018 Nov 11;33:353-360
pubmed: 30117132
Clin Neurol Neurosurg. 2018 Jul;170:120-126
pubmed: 29777944
Int J Mol Sci. 2020 Jan 23;21(3):
pubmed: 31979374
Oncotarget. 2016 Oct 11;7(41):66776-66789
pubmed: 27564260
Clin Neurol Neurosurg. 2011 Sep;113(7):541-7
pubmed: 21507562
Brain Tumor Pathol. 2011 Feb;28(1):59-64
pubmed: 21188541
Neurosurgery. 2017 Aug 1;81(2):230-239
pubmed: 28379547
Neurosurgery. 2020 Jul 06;:
pubmed: 32629469
Cancer. 2012 Mar 15;118(6):1619-27
pubmed: 21837671
J Neurosurg. 2016 May;124(5):1300-9
pubmed: 26544781
J Neurosurg. 2016 Dec;125(6):1408-1419
pubmed: 27015401
J Clin Oncol. 2006 Jun 1;24(16):2563-9
pubmed: 16735709